⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

August 1, 1995Journal of Clinical Oncology

Curing cancer in children: minimizing price, maximizing value.

Anna T. Meadows

View at Publisher

Ask AI

Bookmark

Share

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Abstract

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1995.13.8.1837 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 7636525 Curing cancer in children: minimizing price, maximizing value. A T MeadowsxA T MeadowsSearch for articles by this author https://doi.org/10.1200/JCO.1995.13.8.1837 First Page PDF © 1995 by American Society of Clinical Oncology

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Anna T. Meadows (1995) studied this question.

synapsesocial.com/papers/6a893ef5e0083a7c2c431ee0 https://doi.org/10.1200/jco.1995.13.8.1837

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 related papers. Consider them for comparative context:

1Stereotactic Ablative Radiotherapy Versus Surgical Resection for Early-Stage Non–Small Lung Cancer: An Emulated Target TrialJournal of Clinical Oncology · 2026
2Immunochemotherapy for Borderline Resectable or Locally Advanced Pancreatic Cancer: A Randomized Controlled TrialJournal of Clinical Oncology · 2026
3Methylphenidate for Hematologic Cancer–Related Fatigue: A Randomized Clinical TrialJournal of Clinical Oncology · 2026
4Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.4Journal of Clinical Oncology · 2026
5KEYNOTE-867: A Phase III, Randomized, Double-Blind Study of Stereotactic Body Radiotherapy With Pembrolizumab for Unresected Stage I or II Non–Small Cell Lung CancerJournal of Clinical Oncology · 2026

Darovasertib and Crizotinib First-Line Treatment for Metastatic Uveal Melanoma: Overall Survival, Efficacy, and Safety From the OptimUM-01 StudyJournal of Clinical Oncology · 2026
Art as a Shared Space: Tracing the Unseen Through a Body MapJournal of Clinical Oncology · 2026
PARP Inhibitors in the Management of Ovarian Cancer: ASCO Living Guideline, Version 2026.1.0Journal of Clinical Oncology · 2026
Dalmelitinib Plus Aumolertinib in Advanced NSCLC Patients With EGFR-TKI Resistance and MET Amplification: A Randomized Phase 3 TrialJournal of Clinical Oncology · 2026
COMPANION-002: A Randomized Phase 2/3 Trial of Tovecimig Plus Paclitaxel versus Paclitaxel Alone as a Second-line Therapy in Patients with Advanced Biliary Tract CancerJournal of Clinical Oncology · 2026

More from Journal of Clinical Oncology